By Colin Kellaher

Pfizer Inc. on Wednesday said it has acquired Amplyx Pharmaceuticals Inc., a privately-held developer of therapies for diseases that affect people with compromised immune systems, for an undisclosed amount.

New York-based Pfizer said Amplyx's lead compound, Fosmanogepix, is currently in Phase 2 clinical trials evaluating the safety and efficacy of intravenous and oral formulations for patients with life-threatening invasive fungal infections.

Pfizer said the deal, which expands its anti-infectives pipeline, includes Amplyx's other potential antiviral and antifungal therapies.

Pfizer initially invested in Amplyx in December 2019 as part of a Series C funding round.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

04-28-21 0727ET